Scarica l'app Stockscreener
1.805
0.28%
-0.005
Dopo l'orario di chiusura:
1.83
0.025
+1.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$1.81
Aprire:
$1.82
Volume 24 ore:
1.29M
Relative Volume:
0.53
Capitalizzazione di mercato:
$88.22M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-1.0873
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
-12.38%
1M Prestazione:
-24.79%
6M Prestazione:
-68.55%
1 anno Prestazione:
-92.17%
Intervallo 1D:
$1.71
$1.92
Intervallo di 1 settimana:
$1.71
$2.0599
Portata 52W:
$1.71
$24.67
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.805 | 88.22M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com India
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - TradingView
Can Cabaletta Bio's Conference Appearance Signal New Autoimmune Treatment Progress? - StockTitan
Is Now The Time To Buy Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy - MSN
HC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc (CABA) Stock: Navigating Drops and Gains - The InvestChronicle
Cabaletta Bio (NASDAQ:CABA) Given “Buy” Rating at HC Wainwright - Defense World
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $22.71 - MarketBeat
Shopify Stock Forecast: Can SHOP Hit $175 in 2025? - The Globe and Mail
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Earnings To Watch: Herbalife (HLF) Reports Q4 Results Tomorrow - The Globe and Mail
UPDATECabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - Yahoo Finance
What To Expect From Fiverr’s (FVRR) Q4 Earnings - The Globe and Mail
Cabaletta Bio’s rese-cel shows efficacy in clinical studies - TipRanks
Cabaletta Bio Unveils Promising Clinical Data in RESET Trials - TipRanks
Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings - Marketscreener.com
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications - StockTitan
Kyndryl Soars on AI, Cybersecurity Growth—What’s Next? - The Globe and Mail
Tri Pointe Homes (TPH) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
SG Americas Securities LLC Purchases 8,161 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February - The Manila Times
Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences - Nasdaq
Cabaletta Bio Inc (CABA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Teradata Earnings: What To Look For From TDC - The Globe and Mail
Jennison Associates LLC Cuts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Recent uptick might appease Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners after losing 89% over the past year - Simply Wall St
Company’s Banking Stock: Dissecting a -35.00% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Will Palantir Be the World's Most Valuable Software Company? - The Globe and Mail
Does Cabaletta Bio Inc (CABA) offer a good opportunity for investors? - SETE News
Cabaletta Bio Inc (CABA) Stock: A Value Analysis - The News Heater
BlackRock, Inc. Reduces Stake in Cabaletta Bio Inc: A Strategic Portfolio Adjustment - GuruFocus.com
Cabaletta Bio Inc (CABA) requires closer examination - US Post News
What's Going On With Microsoft Stock? - The Globe and Mail
Market Highlights: Cabaletta Bio Inc (CABA) Ends on a High Note at 2.39 - The Dwinnex
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference - The Manila Times
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire Inc.
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.22%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):